Transforming Outcomes in Hepatocellular Carcinoma: Expert Insights on Applying Evidence to Practice : Episode 13
Treatment Considerations for Advanced HCC in Second Line and Beyond
In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.
EP: 1.Patients With Intermediate Stage HCC Unsuitable for TACE
EP: 2.Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab
EP: 3.Patients With Intermediate Stage HCC Suitable for TACE
EP: 4.HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC
EP: 5.Selecting the Appropriate Frontline Treatment in Advanced HCC
EP: 6.Other Frontline Immunotherapy-based Combinations in Advanced HCC
EP: 7.Patient Profile 2: Advanced HCC Treated with Lenvatinib
EP: 8.Real-World Evidence for Lenvatinib in Advanced HCC
EP: 9.Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab
EP: 10.Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond
EP: 11.Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond
EP: 12.Systemic Immunotherapies for Advanced HCC in Second Line and Beyond
Now Viewing
EP: 13.Treatment Considerations for Advanced HCC in Second Line and Beyond
EP: 14.Management of Child-Pugh B Patients with Advanced HCC
EP: 15.Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023
Related Videos
Related Content
